口服抗栓药与质子泵抑制药相互作用的研究进展  

Research Progress in the Interactions between Novel Antithrombotic Agents and Proton Pump Inhibitors

作　　者：刘书源[1] 苏长海[1] 苏伊新[1] Liu Shuyuan;Su Changhai;Su Yixin(Pharmacy Department of Ordos Central Hospital,Inner Mongolia Ordos 017000,China)

机构地区：[1]鄂尔多斯市中心医院药剂科,内蒙古鄂尔多斯017000

出　　处：《中国药师》2019年第1期137-140,共4页China Pharmacist

摘　　要：通过查阅国内外关于口服抗栓药与质子泵抑制药(PPIs)相互作用的文献,分析总结这两类药物联用在临床实践的应用,探讨口服抗栓药与PPIs相互作用的药理学及临床实践意义。结果表明,PPIs可能会降低氯吡格雷和达比加群的抗栓作用,但其对临床结局的影响尚无定论。目前仍缺乏绝对证据提示何种PPIs能降低抗栓药的疗效,在临床实践中,两类药物联用应遵循指南,严格掌握适应证。Through reviewing the literatures from home and abroad on the interactions between oral antithrombotic agents and proton pump inhibitors( PPIs),the combined application of the two drugs in clinics was analyzed and summarized,and the pharmacological and clinical significance of the combined use was explored. The results showed that PPIs might decrease the antithrombotic efficacy of clopidogrel and dabigatran,while the effects on clinical outcomes were undetermined. At present,there was no absolute evidence suggesting what kind of PPIs can decrease the efficacy of antithrombotic agents. Therefore,the combined use of the two drugs should follow the relevant guidelines and strictly master the indication.

关 键 词：抗血小板药 新型口服抗凝药 质子泵抑制药 药物相互作用 

分 类 号：R969.2[医药卫生—药理学]